Sutent gives metastatic renal cancer patients over 2 years survival

Owen, Olwen Glynn
July 2008
British Journal of Hospital Medicine (17508460);Jul2008, Vol. 69 Issue 7, p378
Academic Journal
The article highlights a study on the ability of sunitinib malate (Sutent) to treat metastatic renal cancer in Great Britain. The study shows that treatment with Sutent gives metastatic renal cancer patients an over two years survival. In addition, Dr. Robert Figlin of the City of Hope National Medical Center has stated that patients treated with sunitib has 11 months progression-free survival, while interferon alpha has five months.


Related Articles

  • Improved survival in advanced liver cancer. Siddall, Rhonda // British Journal of Hospital Medicine (17508460);Jul2008, Vol. 69 Issue 7, p379 

    The article reports on the announcement of further data that sorafenib improves overall survival in patients with advanced liver cancer at the American Society of Clinical Oncology (ASCO) conference in Chicago, Illinois. The author stated the phase III data in 226 Asian patients has showed that...

  • Interferon treatment for Japanese patients with favorable-risk metastatic renal cell carcinoma in the era of targeted therapy. Sazuka, Tomokazu; Nihei, Naoki; Nakamura, Kazuyoshi; Sakamoto, Shinichi; Fukasawa, Satoshi; Komaru, Atsushi; Ueda, Takeshi; Igarashi, Tatsuo; Ichikawa, Tomohiko // Korean Journal of Urology;Mar2015, Vol. 56 Issue 3, p205 

    Purpose: Single-agent interferon (IFN) is no longer regarded as a standard option for first-line systemic treatment of metastatic renal cell carcinoma (RCC) in Western countries. However, some patients with favorable-risk RCC may still achieve complete and long-lasting remission in response to...

  • Lapatinib Moves Forward in Inflammatory and Early HER2-Positive Breast Cancer Trials. Tuma, Rabiya S. // JNCI: Journal of the National Cancer Institute;3/7/2007, Vol. 99 Issue 5, p348 

    The article discusses the lapatinib, a small-molecule tyrosine kinase inhibitor that can be taken orally. The author declares that lapanitib improved disease-free survival in advanced breast cancer patients, may have less cardiac toxic effects than trastuzumab, and may prevent metastases....

  • ONCOLOGY. Kanaike, Megumi // Journal of Pharmacy Practice & Research;2009, Vol. 39 Issue 4, p323 

    The article presents abstracts on oncology research topics which include bleeding risk with vascular endothelial growth factor receptor tyrosine kinase inhibitors sunitinib and sorafenib, use of pemetrexed in non-small cell lung cancer and octreotide in the treatment of metastatic neuroendocrine...

  • P1–080DOES THE USE OF SORAFENIB FOR ADVANCED HCC FOLLOW APPROPRIATE SELECTION CRITERIA? Abdel-Rahman, O. M.; Abdelwahab, M. M.; Shaker, M. K.; Abdelwahab, S. A.; Elbassiony, M. M.; Ellithy, M. M. // Annals of Oncology;Nov2013 Supplement 9, Vol. 24, pix71 

    No abstract available.

  • AXL and acquired resistance to EGFR inhibitors. Postel-Vinay, Sophie; Ashworth, Alan // Nature Genetics;Aug2012, Vol. 44 Issue 8, p835 

    A combination of in vitro and in vivo models with validation in human tumors has identified AXL activation as a new mechanism of acquired resistance to EGFR inhibitors in non-small cell lung cancer. The identification of this mechanism, alongside the current development of specific AXL...

  • The Efficacy of Synchronous Combination of Chemotherapy and EGFR TKIs for the First-Line Treatment of NSCLC: A Systematic Analysis. Yan, Han; Li, Huihui; Li, Qin; Zhao, Pengfei; Wang, Wei; Cao, Bangwei // PLoS ONE;8/18/2015, Vol. 10 Issue 8, p1 

    Background: The combination of chemotherapy and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) currently has become the hotspot issue in the treatment of non-small lung cancer (NSCLC). This systematic review was conducted to compare the efficacy and safety of the...

  • The Role of Pemetrexed Combined with Targeted Agents for Non-Small Cell Lung Cancer. Konopa, Krzysztof; Jassem, Jacek // Current Drug Targets;Jan2010, Vol. 11 Issue 1, p2 

    No abstract available.

  • Breast cancer news from ASCO.  // PharmacoEconomics & Outcomes News;7/10/2010, Issue 607, p3 

    The article deals with several studies presented at the 46th Annual Meeting of the American Society of Clinical Oncology about the costs and outcomes associated with various breast cancer treatments. U.S. researchers revealed the cost effectiveness of letrozole plus lapatinib compared with...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics